Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

Sirona Biochem reports test results for sodium/glucose cotransporter inhibitors

Sep. 22, 2009

Preclinical data on novel lysosomotropic cathepsin K inhibitors presented by Medvir

Sep. 22, 2009

Experiments show TGR5 can be targeted with INT-777 for diabetes and obesity

Sep. 22, 2009

JTT-305 shows promise for the treatment of hypocalcemia and osteoporosis

Sep. 21, 2009

Savient provides update on meeting with FDA for Krystexxa

Sep. 21, 2009

Intarcia Therapeutics commences enrollment in phase II ITCA-650 study

Sep. 21, 2009

Vitamin D3 analogue TEI-K04887 reduces PTH levels without causing hypercalcemia in vivo

Sep. 21, 2009

Arena reports BLOSSOM trial results for weight management

Sep. 21, 2009

Lexicon initiates phase II trial of LX-4211 in type 2 diabetes

Sep. 18, 2009

Hyperion Therapeutics enrolls first patient in HPN-100 trial in children with urea cycle disorders

Sep. 18, 2009

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 10, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Skape Bio unlocks GPCR targets with de novo-designed miniproteins
BioWorld
Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...
Antares Therapeutics divulges new CDK2/cyclin E1 inhibitors
BioWorld Science
Antares Therapeutics Inc. has reported new CDK2/cyclin E1 inhibitors potentially useful for the treatment of cancer.
Empire Discovery Institute, Univ. of Rochester identify IRAK inhibitors
BioWorld Science
Empire Discovery Institute and the University of Rochester have discovered new interleukin-1 receptor-associated kinase 1 (IRAK-1) and/or IRAK-4 inhibitors...